Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 3/20 | 0.51 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.51 |
| ▸ | HTR1A | P08908 | 8/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL69076 | 0.98 | HRH1 (0.50) | HRH1CHRNB2CHRNA4HTR1ASLC6A2 | |
| SCHEMBL27305366 | 0.88 | CHRNB2 (0.50) | CHRNB2CHRNA4HTR1ACHRNB1CHRNB4 | |
| SCHEMBL28331551 | 0.85 | CHRNB2 (0.51) | CHRNB2CHRNA4CHRNB1CHRNB4CHRNA3 | |
| SCHEMBL15000460 | 0.83 | SLC6A2 (0.48) | CHRNB2CHRNA4HTR1ASLC6A2SLC6A4 | |
| SCHEMBL8271730 | 0.82 | ROCK1 (0.47) | HRH1HTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL23761291 | 0.81 | KAT2B (0.48) | CHRNB2CHRNA4CHRNB1CHRNB4CHRNA3 | |
| SCHEMBL4515007 | 0.81 | HRH1 (0.51) | HRH1CHRNB2CHRNA4HTR1ASLC6A2 | |
| Hydrochloric Acid SCHEMBL4123668 | 0.81 | ROCK1 (0.46) | HRH1HTR1ASLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL20764859 | 0.80 | HTR1A (0.54) | HRH1HTR1ASLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL72191 | 0.79 | HRH1 (0.50) | HRH1CHRNB2CHRNA4HTR1ASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10150752-B2 | Substituted triazole derivatives as oxytocin antagonists | IXCHELSIS LIMITED (GB) | 2018-12-11 | — | — | US | disclosed |
| US-20170114040-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LIMITED (GB) | 2017-04-27 | — | — | US | disclosed |
| US-20170114040-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LIMITED (GB) | 2017-04-27 | — | — | US | disclosed |
| US-20170114040-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LIMITED (GB) | 2017-04-27 | — | — | US | disclosed |
| EP-3002278-B1 | GUANIDINE COMPOUND | ASTELLAS PHARMA INC (JP) | 2017-04-19 | — | — | EP | disclosed |
| EP-3002278-B1 | GUANIDINE COMPOUND | ASTELLAS PHARMA INC (JP) | 2017-04-19 | — | — | EP | disclosed |
| US-9556160-B2 | Guanidine compound | ASTELLAS PHARMA INC. (JP) | 2017-01-31 | — | — | US | disclosed |
| US-9556160-B2 | Guanidine compound | ASTELLAS PHARMA INC. (JP) | 2017-01-31 | — | — | US | disclosed |
| US-9556160-B2 | Guanidine compound | ASTELLAS PHARMA INC. (JP) | 2017-01-31 | — | — | US | disclosed |
| US-9394278-B2 | Substituted triazole derivatives as oxytocin antagonists | IXCHELSIS LIMITED (GB) | 2016-07-19 | — | — | US | disclosed |
| US-8207198-B2 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207198-B2 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC. (US) | 2012-06-26 | — | — | US | disclosed |
| EP-1841758-B1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LTD (GB) | 2009-11-18 | — | — | EP | disclosed |
| US-20090253674-A1 | Substituted Triazole Derivatives As Oxytocin Antagonists | PFIZER INC | 2009-10-08 | — | — | US | disclosed |
| US-20090253674-A1 | Substituted Triazole Derivatives As Oxytocin Antagonists | PFIZER INC | 2009-10-08 | — | — | US | disclosed |
| US-20090253674-A1 | Substituted Triazole Derivatives As Oxytocin Antagonists | PFIZER INC | 2009-10-08 | — | — | US | disclosed |
| US-7557131-B2 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC (US) | 2009-07-07 | — | — | US | disclosed |
| EP-1841758-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | Pfizer Limited (GB) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006077496-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| US-20060160786-A1 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114040-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | OXTR, AVPR1B, GNRHR | HRH1 1563/4885CHRNB2 627/4885CHRNA4 696/4885 |
| US-20060160786-A1 | Substituted triazole derivatives as oxytocin antagonists | OXTR, AVPR1B, GNRHR | HRH1 1563/4885CHRNB2 627/4885CHRNA4 696/4885 |
| US-20090253674-A1 | Substituted Triazole Derivatives As Oxytocin Antagonists | OXTR, AVPR1B, GNRHR | HRH1 1563/4885CHRNB2 627/4885CHRNA4 696/4885 |
| US-10150752-B2 | Substituted triazole derivatives as oxytocin antagonists | OXTR, AVPR1B, GNRHR | HRH1 1563/4885CHRNB2 627/4885CHRNA4 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.